Onderzoeker
Thomas Van Looy
- Disciplines:Laboratoriumgeneeskunde, Palliatieve zorg en zorg rond het levenseinde, Regeneratieve geneeskunde, Andere basiswetenschappen, Andere gezondheidswetenschappen, Verpleegkunde, Andere paramedische wetenschappen, Andere translationele wetenschappen, Andere medische en gezondheidswetenschappen
Affiliaties
- Laboratorium Experimentele Oncologie (Afdeling)
Lid
Vanaf16 jul 2009 → 31 okt 2014
Publicaties
1 - 10 van 10
- Efficacy of an innovative, enzyme-activated doxorubicin prodrug in patient-derived dedifferentiated liposarcoma and synovial sarcoma xenograft models(2015)
Auteurs: Jasmien Cornillie, Agnieszka Wozniak, Lise Vreys, Haifu Li, Thomas Van Looy, Jasmien Wellens, Ulla Vanleeuw, Andre Trouet, Peter Pokreisz, Daphne Hompes, et al.
- Therapeutic Efficacy Assessment of CK6, a Monoclonal KIT Antibody, in a Panel of Gastrointestinal Stromal Tumor Xenograft Models(2015)
Auteurs: Thomas Van Looy, Agnieszka Wozniak, Beppe Floris, Haifu Li, Jasmien Wellens, Ulla Vanleeuw, Raf Sciot, Maria Debiec-Rychter, Patrick Schöffski
Pagina's: 112 - 8 - Therapeutic Efficacy Assessment of CK6, a Monoclonal KIT Antibody, in a Panel of Gastrointestinal Stromal Tumor Xenograft Models(2015)
Auteurs: Thomas Van Looy, Agnieszka Wozniak, Beppe Floris, Haifu Li, Raf Sciot, Maria Debiec-Rychter, Patrick Schöffski
Pagina's: 112 - 8 - Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft Models(2014)
Auteurs: Haifu Li, Agnieszka Wozniak, Raf Sciot, Jasmien Cornillie, Thomas Van Looy, Marguerite Stas, Daphne Hompes, Maria Debiec-Rychter, Patrick Schöffski
Pagina's: 665 - 71 - Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumours: rationale and efficacy(2014)
Auteurs: Thomas Van Looy, Agnieszka Wozniak, Beppe Floris, Raf Sciot, Haifu Li, Maria Debiec-Rychter, Patrick Schöffski
Pagina's: 6071 - 82 - Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors(2014)
Auteurs: Anna Quattrone, Agnieszka Wozniak, Barbara Dewaele, Beppe Floris, Thomas Van Looy, Patrick Schöffski, Raf Sciot, Maria Debiec-Rychter
Pagina's: 1510 - 1520 - Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors(2014)
Auteurs: Thomas Van Looy, Yemarshet Kelemework Gebreyohannes, Agnieszka Wozniak, Jasmien Cornillie, Haifu Li, Beppe Floris, Maria Debiec-Rychter, Raf Sciot, Patrick Schöffski
Pagina's: 10 - A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal(2013)
Auteurs: Beppe Floris, Agnieszka Wozniak, Raf Sciot, Haifu Li, Thomas Van Looy, Christophe Deroose, Maria Debiec-Rychter, Patrick Schöffski
Pagina's: 620 - 630 - The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models(2012)
Auteurs: Thomas Van Looy, Agnieszka Wozniak, Patrick Schöffski
Pagina's: 1799 - 1808 - The novel heat shock protein 90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor (GIST) xenografts carrying heterogeneous KIT mutations(2011)
Auteurs: Beppe Floris, Raf Sciot, Agnieszka Wozniak, Thomas Van Looy, Maria Debiec-Rychter, Patrick Schöffski
Pagina's: 5604 - 5614